Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT06507618
This study is recruiting at 6 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer Female
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 65 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of Virginia
- Last updated on ClinicalTrials.gov
- June 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University · New Haven, CT
Virginia · 5
- University of Virginia · Charlottesville, VA
- University of Virginia Community Health · Culpeper, VA
- INOVA Schar Cancer · Fairfax, VA
- Riverside Health System · Newport News, VA
- Virginia Commonwealth University · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.